Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Callisto Pharmaceuticals Inc.

Division of Bausch Health Companies Inc.

Latest From Callisto Pharmaceuticals Inc.

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan

The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.

BioPharmaceutical Deals

Synergy Pharmaceuticals raises $14 million for constipation drug trials

Nasdaq-listed Synergy Pharmaceuticals has raised just under $14 million after expenses in a public offering of shares and warrants. The company said it would use some of the proceeds to fund its gastrointestinal product R&D activities, which include an ongoing Phase II/III trial of plecanatide in chronic constipation and a Phase I trial of SP-333.

Gastrointestinal Cancer

Ironwood raises $50 million for IBS product development

Ironwood Pharmaceuticals has raised $50 million in private equity financing primarily to support the development of linaclotide, its Phase III gastrointestinal compound. The money will fund linaclotide's development in irritable bowel syndrome with constipation (IBS-C) and chronic constipation, as well as its other candidates and commercial expansion.

Gastrointestinal Cancer
See All

Company Information